Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BE-01 is a recombinant alkaline phosphatase enzyme being developed by BiomEdit as a feed additive for animal health. The enzyme is designed to degrade lipopolysaccharides (LPS), which are potent inflammatory stimulants derived from the cell walls of gram-negative bacteria. By neutralizing LPS within the animal's digestive tract, BE-01 aims to reduce inflammation and promote overall gut health. The product is manufactured using synthetic biology to create genetically engineered microbial hosts that produce and secrete the enzyme at scale during fermentation, after which the enzyme is isolated and formulated for oral administration as a feed additive. This approach differs from BiomEdit's lead candidate, BE-101, which utilizes live engineered microbes for delivery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BE-01.